Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

EPI-743 by Edison Pharmaceuticals for noise-induced hearing loss

Also known as: EPI-743, EPI743, Vincerinone, VincerinoneTM, EPI743-14-026, NCT02257983

Edison Pharmaceuticals Inc.

Primary source

Company

Edison Pharmaceuticals Inc.

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Completed

Target Gene

—

Route / Mode

Oral capsules

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, healthy-volunteer, noise-induced, repurposed-drug

Trial IDs

Mechanism

Oral redox-active small molecule/ubiquinone analog evaluated for protection against temporary noise-induced hearing loss, with study keywords indicating oxidative-stress biology.

Indications

Hearing Loss Sensorineural Hearing Loss Noise-Induced Hearing Loss

Notes

Verified as a real Edison-sponsored Phase 2A randomized, placebo-controlled, double-blind study of oral EPI-743/Vincerinone for temporary noise-induced hearing loss. The study is completed; no public hearing-specific results or active follow-on hearing-loss development program were confirmed in this pass. The former EdisonPharma domain now redirects to a domain-sale page, so current ownership/development status should be treated cautiously.

Evidence & Sources

3 structured sources

registry mirror

Supports: canonicalName, aliases, company, allCompanies, programType, modality, mechanism, indications...

IDs: NCT02257983, EPI-743, VincerinoneTM, EPI743-14-026

Open

clinicaltrials

Supports: stage, status, trialIds, sourceUrl

IDs: NCT02257983

Open

domain check

Supports: notes, qaFlags